Pain medicine case reports · 2026
Managing Erythromelalgia-Associated Pain with Suzetrigine: A Case Report.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Hoang Don, Hubbell Jennifer, Verbeek Thomas
Аннотация
BACKGROUND: Erythromelalgia is a rare, debilitating chronic condition characterized by erythema, warmth, and recurrent burning pain typically in the feet. Despite numerous treatment options, management of erythromelalgia can be challenging. Sodium channel blockers are offered as treatment options for erythromelalgia; however, they are often nonselective, limiting their utility. Suzetrigine is a novel, selective Nav1.8 sodium channel inhibitor that appears to have promising antinociceptive potential.
CASE REPORT: Our clinical vignette describes the case of a 23-year-old woman with worsening burning pain in her bilateral feet and ankles, diagnosed as erythromelalgia. Various interventions were trialed without adequate relief, including nonpharmacological management, aspirin, lumbar sympathetic block, and various systemic medications. Suzetrigine was ultimately tried with significant pain relief, making this the first described case of suzetrigine alleviating erythromelalgia-associated pain.
CONCLUSIONS: Overall, our highlights suzetrigine's potentially wide applicability in various pain conditions, although additional clinical trials are still required to clarify the full extent.
CASE REPORT: Our clinical vignette describes the case of a 23-year-old woman with worsening burning pain in her bilateral feet and ankles, diagnosed as erythromelalgia. Various interventions were trialed without adequate relief, including nonpharmacological management, aspirin, lumbar sympathetic block, and various systemic medications. Suzetrigine was ultimately tried with significant pain relief, making this the first described case of suzetrigine alleviating erythromelalgia-associated pain.
CONCLUSIONS: Overall, our highlights suzetrigine's potentially wide applicability in various pain conditions, although additional clinical trials are still required to clarify the full extent.